<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963362</url>
  </required_header>
  <id_info>
    <org_study_id>GLA5PR-107</org_study_id>
    <nct_id>NCT03963362</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of GLA5PR Tablet According to the Renal Function</brief_title>
  <official_title>Clinical Study to Evaluate Pharmacokinetics of GLA5PR Tablet According to the Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evauate pharmacokinetics of GLA5PR tablet according to the renal function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Cmax of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUClast of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>AUClast</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, 72 hours after administration</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2beta of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>t1/2beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>CL/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F of Pregabalin</measure>
    <time_frame>Pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 48, and 72 hours after administration</time_frame>
    <description>Vz/F</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 75 mg as 60~89 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 75 mg as 60~89 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 75 mg over 90 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 75 mg over 90 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 150 mg as 60~89 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 150 mg as 60~89 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 150 mg over 90 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 150 mg over 90 mL/min(CLcr)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Administration of GLA5PR 75 mg as 30~59 mL/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of GLA5PR 75 mg as 30~59 mL/min(CLcr)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA5PR tablet 75 mg</intervention_name>
    <description>GLARS-NF3 tablet</description>
    <arm_group_label>Administration of GLA5PR 75 mg as 30~59 mL/min</arm_group_label>
    <arm_group_label>Administration of GLA5PR 75 mg as 60~89 mL/min</arm_group_label>
    <arm_group_label>Administration of GLA5PR 75 mg over 90 mL/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLA5PR tablet 150 mg</intervention_name>
    <description>GLARS-NF3 tablet</description>
    <arm_group_label>Administration of GLA5PR 150 mg as 60~89 mL/min</arm_group_label>
    <arm_group_label>Administration of GLA5PR 150 mg over 90 mL/min</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subject who, at the time of screening, are the age between 19 and 64 years&#xD;
&#xD;
          -  Subject who has body weight more than 50 kg (45 kg in women), and less than 80 kg&#xD;
&#xD;
          -  Subject who normal renal function of the creatinine clearance calculated by&#xD;
             Cockcroft-Gault equation over 90 mL/min&#xD;
&#xD;
          -  Subject who the mild renal function of the creatinine clearance between 60 and 89&#xD;
             mL/min calculated by Cockcroft-Gault equation&#xD;
&#xD;
          -  Subject who the moderate renal patient of the creatinine clearance between 30 and 59&#xD;
             mL/min calculated by Cockcroft-Gault equation&#xD;
&#xD;
          -  Subject who is clinically no significant by a medical history, physical, and&#xD;
             psychological examination&#xD;
&#xD;
          -  Subject who clinically no significant a vital sign with Investigator's judgment&#xD;
&#xD;
          -  Subject who has result of diagnostic laboratory test excluding the items described in&#xD;
             exclusion criteria of the 13, and 14, and judged to be clinically no significant when&#xD;
             medically by investigator&#xD;
&#xD;
          -  Subject who has consented to use a combination of effective contraceptive methods or&#xD;
             medically appropriate contraceptive methods from the first administration of the&#xD;
             clinical trial drug to the end of the clinical trial (when testing for final safety&#xD;
             evaluation) and not to provide sperm or egg&#xD;
&#xD;
          -  Subject who is negative the serum and urine hCG test, and is not to pregnant and&#xD;
             feeding&#xD;
&#xD;
          -  Subject who signed and dated the informed consent form after understanding fully to&#xD;
             hear a detailed explanation in the clinical trial&#xD;
&#xD;
          -  Subject who is accept to the post-study visit and to be willing to providing of&#xD;
             collection the blood, and urine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who is any history of gastrointestinal disease (e.g., Crohn's disease, and&#xD;
             others), and surgery (except for simple appendectomy or repair of a hernia), which can&#xD;
             influence the absorption of investigational products&#xD;
&#xD;
          -  Subject who has a history of hypersensitivity or clinically significant&#xD;
             hypersensitivity reactions to drugs or other drugs (aspirin, antibiotics, etc.) that&#xD;
             contain components of the clinical trial drug or components of the same class (except&#xD;
             for inactive allergic rhinitis)&#xD;
&#xD;
          -  Subject who is genetic problem such as galactose intolerance, or Lapp lactose&#xD;
             dehydrogenase deficiency, or glucose-galactose uptake disorder&#xD;
&#xD;
          -  Subject with the exclusion criteria of 1 to 3, or a significant disease (epilepsy,&#xD;
             etc.) and past disease that is considered difficult to participate in clinical trials&#xD;
             according to the investigator's judgement&#xD;
&#xD;
          -  Subject who had whole blood donation within 60 days or component blood donation within&#xD;
             30 days before the first administration of the investigational product, or transfusion&#xD;
             within 60 days before the first administration&#xD;
&#xD;
          -  Subject who has participated in any other clinical trials and had medication within&#xD;
             180 days prior to the first administration of investigational product&#xD;
&#xD;
          -  Subject who has taken any ethical-the-counter drug or has taken any over-the-counter&#xD;
             drug within 14 days before the screening visit, except to the taken the&#xD;
             prior-medication for the disease treatment&#xD;
&#xD;
          -  Subject who has taken any oriental medicines or any dietary supplements within 30&#xD;
             days, before the screening visit&#xD;
&#xD;
          -  Subject who has taken any heavy drinking within 30 days before the screening visit&#xD;
             (&gt;21 units/week)&#xD;
&#xD;
          -  Subject who has taken a food expected to have an effect on the clinical trial within 7&#xD;
             days, before the screening visit; The food of contained in caffeine (&gt; 2 times/day)&#xD;
             The products containing grapefruit (&gt; 2 times/day)&#xD;
&#xD;
          -  Subject who has shown positive reaction to drugs that may be abused from a urine drug&#xD;
             screening&#xD;
&#xD;
          -  Subject who is positive result in smoking or urine nicotine test within 30 days,&#xD;
             before the screening visit&#xD;
&#xD;
          -  Subject who is positive result in serum test (hepatitis type B test, hepatitis type C&#xD;
             test, Human Immunodeficiency Virus (HIV) test, and syphilis test), during the&#xD;
             screening period&#xD;
&#xD;
          -  Subject who showed the following findings in the tests conducted during the screening&#xD;
             period;&#xD;
&#xD;
          -  Less than the lower normal limit (LNL) in the Hb.&#xD;
&#xD;
          -  In excess of 1.5 times the upper normal limit (UNL) in the hepatic enzyme (AST and&#xD;
             ALT), and the alkaline phosphatase values&#xD;
&#xD;
          -  In excess of 1.5 times the upper normal limit (UNL) in the total bilirubin&#xD;
&#xD;
          -  Subject who is QTc &gt; 450 msec in ECG or a clinically significant abnormal rhythm&#xD;
             during the screening period&#xD;
&#xD;
          -  Subject who is not eligible person for the clinical trial according to the&#xD;
             investigator's judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minchang Kwon, Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>GL PharmTech Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong Hyuk Jung, MS</last_name>
    <phone>82-31-739-5220</phone>
    <phone_ext>404</phone_ext>
    <email>jhjung@glpt.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeong-Seok Lim, MD, Ph D.</last_name>
    </contact>
    <investigator>
      <last_name>Hyeong-Seok Lim, MD, Ph D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLA5PR</keyword>
  <keyword>Renal function</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pregabalin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

